Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Capecitabine and Bevacizumab ± Vinorelbine as 1st Line Treatment in HER-2 Negative Metastatic or Locally Advanced Inoperable Breast Cancer Patients

NCT00868634 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.

NCT NCT00868634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00868634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Capecitabine and Bevacizumab ± Vinorelbine as 1st Line Treatment in HER-2 Negative Metastatic or Locally Advanced Inoperable Breast Cancer Patients
Lead sponsor
iOMEDICO AG
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2009
Completion date
October 31, 2015
Enrollment
600 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer